Kornimate/medical-research-clean huggingface dataset:
bronchial dilation test in wheezy infants

Conditions: Asthma

Summary: the purpose of the study is to establish the methodology of bronchial dilation test by salbutamol mdi with spacer in wheezy infants with asthma and to evaluate the effects of atopy on the exacerbation of wheeze in wheezy infants.

after screening,each participant undergo baseline pulmonary function test(jaeger master screen baby body, germany)and post-bronchodilator measurements that performed 10min after 200ug of salbutamol administered using a metered-dose inhaler and a spacer. the participants undergo baseline lung function test and bronchial dilation tests on the second and third visits with one-month interval,and whenever there is an exacerbation.

Eligibility criteria:
inclusion criteria: * normal term infants.recurrent wheezing with or without atopy,none of the subjects had a history of respiratory illness, congenital heart disease,dysphagia,oxygen saturation≤90% on room air,an active seizure disorder,or upper airway obstruction,or requirement for assisted ventilation in the neonatal periods,all infants were asymptomatic for at least 2 weeks preceding the test. exclusion criteria: * subjects had a history of respiratory illness, congenital heart disease,dysphagia,oxygen saturation≤90% on room air,an active seizure disorder,or upper airway obstruction,;all infants were asymptomatic for at least 2 weeks preceding the test.

Keywords: infants asthma bronchial dilation test plethysmography
feasibility of a community-based dance program for latino older adults

Conditions: Mobility Limitation

Summary: the objective of this study is to evaluate the feasibility and preliminary effectiveness of activate bailando, a 6-week community-based dance class offered in spanish to older adults. 20 older adults in the madison, wisconsin area who are enrolled in activate bailando will complete a pre-and post-program test within 10 days for program start and completion.

the primary aim is to evaluate the feasibility of the activate bailando program based on measures of recruitment, retention, attendance, and acceptability. the secondary aim is to evaluate the preliminary effectiveness of the program on metrics of balance, mobility, social connectedness, and fear of falling.

Eligibility criteria:
inclusion criteria: * being over the age of 55 * willing and able to participate in the activate bailando class * willing and able to complete data collection before and after the program exclusion criteria: * not being over the age of 55 * not willing and able to participate in the activate bailando class * not willing and able to complete data collection before and after the program

Keywords: hispanic/latinos older adults
effect of seated exercises and psychoeducational rehabilitation on fatigue and coping of women postmastectomy

Conditions: Fatigue; Coping Behavior

Summary: this study aimed to examine the effect of bundling seated exercises and psychoeducational rehabilitation using the teach-back approach on fatigue and coping of women postmastectomy. hypotheses for research: 1. women with bc who receive seated exercises and psychoeducational rehabilitation using the teach-back approach after mastectomy exhibit less fatigue than those who do not. 2. women with bc who receive seated exercises and psychoeducational rehabilitation using the teach-back approach after mastectomy exhibit improved coping behaviors than those who do not. a quasi-experimental research was conducted in the main university hospital, alexandria, egypt. a total of 60 women were randomly allocated to one of two groups.; women in the study group practiced seated exercises and psychological rehabilitation interventions, including mindfulness breathing, problem-solving training, cognitive reframing technique, and thought stopping.

a quasi-experimental research was conducted in the main university hospital, alexandria, egypt. a total of 60 women were randomly allocated to one of two groups.; women in the study group practiced seated exercises and psychological rehabilitation interventions. researchers prepared a health education unit and designed a booklet about seated exercises and psychological interventions. the developed program was applied to each patients using teach-back method. seated exercises in the sitting position, women were instructed to perform different types of exercises. researchers demonstrated each exercise and asked women to practice preoperatively to be ready for re-demonstrating them after surgery. patients were asked to perform the exercise repeatedly until mastering the necessary skills. psychological rehabilitation the participants received training about the implementation of four psychological interventions, namely mindfulness breathing, problem-solving training, cognitive reframing, and thought stopping. follow-up women were instructed to practice each exercise ten times and repeat the whole activity five times per day. women were followed up for two months to ensure their commitment to the program and provide the needed support.

Eligibility criteria:
inclusion criteria: * female * adult * fully conscious * having breast cancer * planned for mastectomy exclusion criteria: - hemodynamically unstable

Keywords: breast cancer exercise intervention psychoeducation teach-back fatigue coping
study of the safety and efficacy of regn727/sar236553 in patients with hefh hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to assess the efficacy and safety of regn727/sar236553 in participants diagnosed with heterozygous familial hypercholesterolemia (hefh)


Eligibility criteria:
inclusion criteria: 1. must meet the world health organization criteria for hefh 2. participants must be on a stable statin dose, with or without ezetimibe, for at least 6 weeks before screening 3. serum ldl-c levels ≥ 100 mg/dl at screening 4. willing to follow the ncep atpiii tlc diet, or an equivalent diet plan, starting at screening and continuing until the last study visit 5. a negative urine/serum pregnancy test at each screening visit and start of the study, for women of childbearing potential key exclusion criteria: 1. participants with homozygous fh (clinically or by previous genotyping) 2. use of a medication (other than a statin or eze) to alter serum lipids within 42 days (6 weeks) before screening including, but not limited to: * fibrates * niacin (\>500 mg/day) * omega-3 fatty acids (\>1000 mg/day of dha/epa) * bile acid resins 3. use of nutraceuticals or otc medications that may alter lipid levels that are not stable for at least 6 weeks before screening and are not planned to remain constant throughout the study. examples include: * omega-3 fatty acids (≤1000 mg/day of dha/epa) * niacin (≤500 mg/day) * plant stanols, such as found in benecol, flax seed oil, psyllium * red yeast rice 4. disorders known to influence lipid levels, such as nephrotic syndrome, significant liver disease, cushing's disease, untreated hypothyroidism (patients on stable thyroid replacement for at least 12 weeks before the full screening visit, who are metabolically euthyroid by thyroid-stimulating hormone (tsh) testing are allowed) 5. use of thyroid medications (except for replacement therapy which has been stable for at least 12 weeks before the full screening visit) 6. fasting serum tg \>350 mg/dl screening 7. ldl apheresis within 12 months before screening
an international phase 2 study of su011248 in patients with inoperable liver cancer

Conditions: Liver Neoplasms; Unresectable Hepatocellular Carcinoma

Summary: the study will consist of two parts. in part 1 the study will start enrolling 38 patients and then further 25 patients up to a total of 63 eligible patients. if the study gives good results it can be expanded to a total of 160 patients. su011248 will be administered orally daily for 4 weeks followed by a 2-week rest at a starting dose of 50 mg \[milligrams\] with provision for dose reduction based on tolerability. all patients will receive repeated cycles of su011248 until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. after discontinuation of treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of hepatocellular carcinoma * patients must present with disease not amenable to curative surgery (i.e. either hepatectomy, or liver transplant). * evidence of measurable disease by radiographic technique * adequate organ function. exclusion criteria: * prior treatment with any systemic treatment for liver cancer * presence of clinically relevant ascites * severe hemorrhage \<4 weeks of starting study treatment. * diagnosis of second malignancy within last 3 years * history of or known brain metastases, spinal cord compression, or carcinomatous meningitis * known human immunodeficiency virus (hiv) * serious acute or chronic illness * current treatment on another clinical trial * pregnant or breastfeeding

Keywords: liver neoplasms, sunitinib, phase 2
a study to evaluate the efficacy and safety of hrg2010 in parkinson's disease with motor fluctuations

Conditions: Parkinson's Disease

Summary: the study is a multicenter, randomized, double-blind, double-dummy, active-controlled, phase iii clinical study. the aim of this trial is to evaluated the efficacy and assessed the safety of hrg2010 compared with a sustained-release cabridopa-levodopa formulation in parkinson's disease with motor fluctuations.


Eligibility criteria:
inclusion criteria: 1. male or female who are at age 40\~80 years with pd, consistent with the international parkinson and movement disorder society clinical diagnostic criteria and who are being treated with stable regimens of ddci+ld but experiencing motor fluctuations. 2. mini mental state examination (mmse) ≥ 24 at screening visit. 3. hoehn and yahr stage i-iv when "on" at screening visit. 4. at screening, the participant has predictable "off" periods. 5. able and willing to provide a written informed consent. exclusion criteria: 1. diagnosed with atypical or secondary parkinsonism. 2. history of narrow angle glaucoma、peptic ulcer disease or upper gastrointestinal hemorrhage. 3. had prior functional neurosurgical treatment for pd or if such procedure(s) are planned or anticipated during the study period. 4. nonresponsive to ld therapy. 5. in the opinion of the clinical investigator, subjects who should not participate in the study. 6. subjects who are allergic to the investigational drug to be used in this study. 7. pregnant or breastfeeding. 8. participants who have previously participated in an hrg2010 study.
an efficacy study of canagliflozin or sitagliptin to determine glucose variability in mexican participants with type 2 diabetes mellitus inadequately controlled on metformin

Conditions: Diabetes Mellitus, Type 2

Summary: the main purpose of this study is to assess the effects of 4 weeks each of daily treatment with canagliflozin 300 milligram (mg) versus sitagliptin 100 mg as treatment adjuncts to metformin (at stable dosages) on intrapatient glycemic coefficient of variation (cv), expressed as a ratio percentage of standard deviation (sd) to mean glucose levels.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * inadequate glucose control while using metformin monotherapy (met) for at least 8 weeks at stable daily doses of at least 1500 milligram (mg) before screening visit (visit 1) a. hemoglobin a1c (hba1c) equal to (=) 7.5 percent (%) to 10.5% at visit 1 * adequate qualifying continuous glucose monitoring (cgm) reading during the pre-randomization (selection) phase * estimated glomerular filtration rate (egfr) of at least 60 milliliter/minute (ml/min)/1.73 meter square (m\^2) at visit 1 * body mass index of 22 through 45 kilogram per meter square (kg/m\^2) at visit 1 exclusion criteria: * history of any of the following (at visit 1): 1. diabetic ketoacidosis (dka) 2. type 1 diabetes mellitus (t1dm) 3. pancreatic (for example, beta-islet cell) transplantation 4. diabetes secondary to pancreatitis or pancreatectomy 5. personal history of, or ongoing, pancreatitis 6. one or more episodes of severe hypoglycemia (requiring assistance from others), as documented in the history obtained at visit 1 7. hereditary glucose-galactose malabsorption or primary renal glucosuria * repeated fasting plasma glucose (fpg) or fasting self-monitored blood glucose (smbg) greater than (\>) 270 milligram per deciliter (mg/dl) during the pre-treatment phase * treatment with any other oral or parenteral antidiabetic medications different from metformin monotherapy, including but not limited to dipeptidyl peptidase-4 (dpp-4) inhibitors, sulphonylureas, thiazolidinediones, insulins and glucagon-like peptide-1 receptor agonist (glp-1ras); sodium-glucose co-transporter 2 (sglt-2) inhibitors and investigational agents * received an investigational drug or vaccine or used an invasive investigational medical device within 30 days before the planned first dose of study drug * current use of "natural medicines" or natural medicinal products for diabetes (for example, cactus-derived nutrients, celery)
pilot evaluation of 124i-iodo-azomycin galacto-pyranoside (*iazgp) positron emission tomography (pet) in the imaging of hypoxic tumors

Conditions: Cervical Cancer; HEENT Cancer; Renal Cancer; Uterine Cancer; CERVIX UTERI NOS; RECTUM

Summary: the purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. these low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. a tracer is an extremely small quantity of a substance. tracer to which radioactivity has been attached may be used to "trace" events in the body. a tracer called iodo-azomycin galactopyranoside (or \*iazgp) appears to be able to detect low oxygen areas within tumor. radioactive iodine in this molecule can be detected by an imaging technique called a pet scan. this present study involves obtaining three scans using this new imaging technique. the goal of carrying out many scans is to determine which scan will best show any areas in your tumor that may have low levels of oxygen.


Eligibility criteria:
inclusion criteria: * patients must have locally advanced cancer as determined by currently accepted diagnostic work-up, including ct/mr/us. * kps \>70%. * patients must be \> or equal to 18 years of age. exclusion criteria: * patients will be excluded from the study if they fulfill any of the following criteria: * patients with abnormal baseline thyroid function tests, or any thyroid disorder including but not limited to hypothyroidism and thyroiditis. patients with thyroid cancer who have had a thyroidectomy are not excluded. * patients who are pregnant or lactating. * mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study. * patients who cannot tolerate being in the pet scanner for the duration of the study.

Keywords: measurable disease locally advanced disease
robotic-arm assisted ga-68 psma pet/ct guided transgluteal prostate biopsy

Conditions: Prostate Cancer

Summary: gallium-68 prostate-specific-membrane-antigen (ga-68 psma) pet/ct is being used in prostate cancer imaging. in the present study, we aimed to evaluate the efficacy and safety of robotic arm-assisted ga-68 psma pet/ct-guided transgluteal prostatic biopsy. seventy-eight participants with a clinical suspicion of pca were recruited from january 2019 to september 2020. all the patients underwent whole-body ga-68 psma pet/ct. the patients with psma-avid lesion in the prostate underwent robotic arm-assisted pet-guided transgluteal biopsies. the degree of pain during the procedure, procedure-related complications and histopathology were evaluated.


Eligibility criteria:
inclusion criteria: i. clinically or biochemically suspected cases of ca prostate. ii. patients with psma avid lesion in the prostate iii. patients, who were ready to give written informed consent for biopsy iv. in good general condition (karnofsky performance status, kps, of more than 70). exclusion criteria: i. no focal psma expressing lesion in the prostate ii. patients who refused to give written informed consent iii. abnormal coagulation profile iv. acute prostatitis, any severe acute or chronic medical condition

Keywords: positron emission tomography computed tomography glu-nh-co-nh-lys-(ahx)-((68)ga(hbed-cc)) biopsy
dietary calcium supplementation, gut permeability and microbiota in type 2 diabetics

Conditions: Type 2 Diabetes Mellitus; Overweight

Summary: dietary calcium seems to act on glycemic control, favoring the prevention and treatment of type 2 diabetes mellitus (dm2). it is possible that calcium modulates gut microbiota and increase the integrity of the intestinal mucosa. this study aims to evaluate the effects of dietary calcium supplementation in permeability and intestinal microbiota in overweight type 2 diabetics. this is a single-blind, randomized, placebo-controlled, crossover study. patients (n=20) with low habitual calcium intake will be allocated in control group (control) or test group (dairy). hypocaloric diets (restriction of 500 kcal / day) will be prescribed containing 800 mg of calcium from dietary sources / day. during intervention period, a beverage (shake) (control - without the addition of calcium sources or dairy - 700 mg of calcium as milk powder) will be ingested in the laboratory. food intake, body composition (total body fat and fat free mass) and anthropometric measures (waist circumference, waist-hip ratio, waist-height, neck circumference and sagittal abdominal diameter) will be evaluated at baseline and at the 6th and 12th weeks. physical activity level, gut permeability, gut microbiota, and biochemical parameters (parathyroid hormone, 25-dihydroxy vitamin d, calcium, fasting glucose, fasting insulin, fructosamine, hemoglobin, hba1c, uric acid, triglycerides, cholesterol total and partial, lipopolysaccharide, inflammatory markers) will be evaluated at baseline and after 12 weeks. the statistical analysis will be performed with the use of spss software (spss inc., chicago, il, 2008, version 17.0). parametric or non-parametric tests will be applied, according to the distribution of variables (level of statistical significance of 5%).


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus using oral hypoglycemic medication * overweight (body mass index between 25 and 34.9 kg / m2) * usual intake of calcium less than 600 mg / day * level of physical activity light to moderate * hba1c above 7% or fasting glucose above 130 mg / dl exclusion criteria: * smoking * use of calcium, vitamin d, magnesium, zinc, chromium, copper supplements or medication affecting the metabolism of these micronutrients, * use of drugs, herbs or diets that reduce appetite and body weight * estrogen replacement * gain or loss of at least 5 kg in the last 3 months * recent change in the level of physical activity * aversion or intolerance to food provided in the study * alcohol consumption of more than 2 doses / day (more than 50g ethanol / day) * eating disorders * endocrine disease, renal disease, hepatic disease or malabsorption syndrome that alters calcium metabolism * history of recurrent nephrolithiasis * caffeine consumption of\> 300 mg / day * pregnancy, lactation or postmenopausal * anemia * cardiovascular, infectious, inflammatory, thyroid, liver, kidney or intestinal disease * use of anti-inflammatory, antacids, antibiotics and laxatives drugs * major gastrointestinal surgery.
effects of 4-ap on functional sci recovery

Conditions: Spinal Cord Injury

Summary: the purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (sci). the fda approved drug, dalfampridine (4-ap). 4-ap will be used in combination of spike-timing-dependent plasticity (stdp) stimulation and stdp stimulation with limb training.

currently, research has shown that 4-ap has a positive effect on sensory and motor function rehabilitation in humans with chronic sci in addition to decreasing recorded spasticity, increased sensation, and decreased pain. utilizing limb training to promote recovery of motor function is enhanced by eliciting stdp in the limbs. an important strength of this aim is the combination of training and stdp, which aims at enhancing the beneficial effects of motor training by promoting plasticity in the corticospinal pathway. we hypothesize that introducing 4-ap into the stdp stimulation and stdp stimulation with lower-limb training will further improve motor function rehabilitation in patients with chronic sci.

Eligibility criteria:
inclusion criteria: * male and females between ages 18-85 years * sci at least 4 weeks post injury * spinal cord injury at or above l2 * asia a,b,c, or d, complete or incomplete * possess the following abilities * the ability to perform a small visible contraction with dorsiflexion and hip flexor muscles exclusion criteria: * uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease * any history of renal impairment * any debilitating disease prior to the sci that caused exercise intolerance * premorbid, ongoing major depression or psychosis, altered cognitive status * history of head injury or stroke * vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication * history of seizures or epilepsy * receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2) * pregnant females * if a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, ms, or herniated disk * metal plate in skull * individuals with scalp shrapnel, cochlear implants, or aneurysm clips * individuals taking bupropion, dolutegravir, lacosamide, trilaciclib, or pr interval prolonging drugs

Keywords: sci neural control 4-ap walking neuroplasticity